Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CARBOPLATIN for B-cell lymphoma refractory: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 21 adverse event reports in the FDA FAERS database where CARBOPLATIN was used for B-cell lymphoma refractory.

Most Reported Side Effects for CARBOPLATIN

Side Effect Reports % Deaths Hosp.
Off label use 6,100 7.3% 957 2,160
Neutropenia 5,314 6.3% 672 1,919
Anaemia 5,312 6.3% 592 2,761
Febrile neutropenia 4,888 5.8% 846 3,033
Nausea 4,588 5.5% 489 2,306
Disease progression 4,538 5.4% 1,159 618
Thrombocytopenia 4,483 5.3% 604 1,928
Malignant neoplasm progression 4,177 5.0% 1,068 971
Diarrhoea 4,154 4.9% 583 2,581
Dyspnoea 3,494 4.2% 463 1,867
Drug ineffective 3,377 4.0% 854 802
Vomiting 3,303 3.9% 439 2,027
Pyrexia 3,116 3.7% 352 2,297
Pancytopenia 2,910 3.5% 563 1,921
Fatigue 2,857 3.4% 356 1,235

Other Indications for CARBOPLATIN

Non-small cell lung cancer (7,939) Ovarian cancer (5,850) Product used for unknown indication (5,003) Breast cancer (4,036) Lung adenocarcinoma (3,888) Lung neoplasm malignant (3,487) Triple negative breast cancer (3,195) Small cell lung cancer (1,991) Chemotherapy (1,902) Diffuse large b-cell lymphoma (1,843)

Other Drugs Used for B-cell lymphoma refractory

RITUXIMAB (103) OBINUTUZUMAB (84) CISPLATIN (53) ETOPOSIDE (49) DEXAMETHASONE (45) AXICABTAGENE CILOLEUCEL (44) CYCLOPHOSPHAMIDE (43) CYTARABINE (40) IBRUTINIB (39) LENALIDOMIDE (36)

Related Pages

CARBOPLATIN Full Profile All B-cell lymphoma refractory Drugs CARBOPLATIN Demographics CARBOPLATIN Timeline